Lantheus (NASDAQ:LNTH) Shares Down 2.2% – Should You Sell?

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s share price traded down 2.2% during trading on Friday . The stock traded as low as $89.62 and last traded at $89.96. 363,405 shares traded hands during trading, a decline of 64% from the average session volume of 1,011,764 shares. The stock had previously closed at $91.94.

Wall Street Analysts Forecast Growth

LNTH has been the subject of several research analyst reports. Redburn Atlantic began coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective for the company. JMP Securities dropped their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Truist Financial reiterated a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, The Goldman Sachs Group initiated coverage on shares of Lantheus in a report on Wednesday. They set a “buy” rating and a $143.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $131.86.

Lantheus Stock Down 1.6 %

The stock has a 50-day simple moving average of $96.63 and a two-hundred day simple moving average of $98.18. The firm has a market cap of $6.29 billion, a PE ratio of 15.05 and a beta of 0.45.

Institutional Trading of Lantheus

A number of institutional investors have recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB purchased a new stake in Lantheus in the 3rd quarter worth approximately $25,000. Signaturefd LLC lifted its stake in Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares during the period. Nkcfo LLC purchased a new position in Lantheus during the 2nd quarter valued at $47,000. UMB Bank n.a. raised its holdings in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. bought a new position in Lantheus in the 3rd quarter worth $51,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.